# About Medicinal PT-141: An Editorial PT-141 Research Digest

> Medicinal PT-141 is an independent editorial project publishing cited summaries of the PT-141 (bremelanotide) research record. Not a clinic, not a pharmacy, not a vendor.

An independent editorial digest of the published research on PT-141 (bremelanotide) — read like a calm clinical platform, owned by no clinic and selling nothing.

## What this site is

Medicinal PT-141 is an independent editorial project that publishes summaries of the peer-reviewed research literature on PT-141 (bremelanotide). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product, and we do not source or facilitate access to one. Our work is editorial commentary on publicly available science — the trials, the FDA label, and the reviews — organized to be read clearly.

## Why "medicinal," and what it does not mean

PT-141 (bremelanotide) is the unusual research compound that is also a real FDA-approved finished drug — approved in 2019 for HSDD in premenopausal women [6]. The "medicinal" in this site's name reflects that medical reality and the editorial position we take toward it: reading the compound through what it is studied and approved for. It is a stance relative to the literature, not a claim about services. We dispense nothing, prescribe nothing, and consult on nothing. The calm clinical-platform presentation is a reading interface, not a healthcare offering.

## How we handle evidence

Every quantitative clinical claim on this site is tied to a numbered citation that resolves to a real study or the FDA label. We keep two layers strictly apart: cited clinical evidence (the RECONNECT trials, the 52-week extension, the fMRI mechanism study, the label pharmacokinetics) and a clearly-labeled field-reports layer of unverified community experience, which carries no citations because it has none. We foreground tolerability honestly — including nausea, the cardiovascular signal, and hyperpigmentation — rather than burying it, and we keep the effect-size debate in plain view. Where the evidence is preliminary or off-label, we say so.

## What we are not

We are not a healthcare provider, a telehealth service, a compounding pharmacy, or a vendor. There is no "our medical team" here and no physical clinic behind this site. Nothing on these pages is a recommendation to obtain or self-administer any substance. For anything involving the approved drug and the approved indication, that is a matter for a licensed clinician — not for this digest, which exists only to organize and cite the published record.

---

A calm clinical-platform reading of the bremelanotide record, read in low light — the approved-for-premenopausal-HSDD-only scope surfaced first, the cited trial and label evidence flagged green, the unverified field reports fenced off amber; no clinic behind the platform and nothing here prescribed, dispensed, or sold.